Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024


Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, after market close on Thursday, May 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor Relations section under the "Company" tab at www.twistbioscience.com.

The conference call will be webcast live through the Investor Relations section under the "Company" tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company's Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on LinkedIn | X | YouTube | Instagram


These press releases may also interest you

at 10:30
TrueFort Named to Citizens JMP Cyber 66 List of Hottest Private CyberSecurity Companies
TrueFort, the lateral movement protection company, today announced it was named to the Citizens JMP Cyber 66 report for the second year in a row. In the annual report, Citizens JMP's experts identify private cybersecurity companies that are...

at 10:20
OpenText Completes Divestiture of Application Modernization and Connectivity (AMC) Business to Rocket Software for $2.275B
Open Text Corporation , , today announced that it has successfully completed the divestiture of its AMC/Mainframe business to Rocket Software, Inc., a Bain Capital portfolio company ("Rocket Software"), for $2.275 billion in cash before taxes, fees...

at 10:19
Casio America, Inc. Appoints Shermeen Greenmun as Vice President of the Timepiece Division
Casio America, Inc. announced today the appointment of Shermeen Greenmun as the Vice President of the Timepiece Division. With over 25 years of expertise in fine horology and luxury jewelry, Greenmun brings a wealth of knowledge that will further the...

at 10:17
FDA Clarifies Approach to Genomic Alterations in Animals
Today, the U.S. Food and Drug Administration took important steps to advance the FDA's regulatory process for intentional genomic alterations (IGAs) in animals. The updated guidance documents underscore the agency's commitment to further modernize...

at 10:15
SecondWave Systems Demonstrates Reduction in Disease Activity in Clinical Study Evaluating Novel Ultrasound-Based Anti-Inflammatory Therapy in Rheumatoid Arthritis
SecondWave Systems, Inc., a pioneer in the emerging field of bio-ultrasonic medicine, today announced completion of a pilot clinical study evaluating its novel noninvasive ultrasound stimulation technology in the treatment of patients with rheumatoid...

at 10:15
Engage Technologies Group and APX Platform Unveil Bold Rebrand as Clarity Technologies
Engage Technologies and APX Platform have revealed their new brand identity as Clarity Technologies. In uniting these two companies and combining their product offerings into one unique platform, the rebranding initiative underscores a commitment to...

More news about Science and technology...


News published on and distributed by: